Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional survival of patients without disease progression highlights that NLR and ECOG are the factors that most accurately predict the probability of long survival. The 3-year conditional survival of patients with disease progression showed a medium effect size for HCV status, alpha-fetoprotein and NLR at all time-points. Macro-vascular portal vein invasion, extra hepatic disease, and BCLC we have a large effect size at 6 months and a medium effect size at 12 and 24 months.Our findings support the use of baseline NLR for the identification of patients with a higher probability of long-survival. NLR should be used as a stratification factor in the forthcoming clinical trials on the drugs for the advanced HCC now in pipeline.

Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib / Casadei-Gardini, A.; Dadduzio, V.; Rovesti, G.; Cabibbo, G.; Vukotic, R.; Rizzato, M. D.; Orsi, G.; Rossi, M.; Guarneri, V.; Lonardi, S.; D'agostino, D.; Celsa, C.; Andreone, P.; Zagonel, V.; Scartozzi, M.; Cascinu, S.; Cucchetti, A.. - In: MEDICINE. - ISSN 1536-5964. - 99:22(2020), pp. 1-6. [10.1097/MD.0000000000019958]

Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib

Rovesti G.;Andreone P.;Cascinu S.;
2020

Abstract

Sorafenib is the first multikinase inhibitor demonstrating a survival benefit for patients suffering from advanced hepatocellular carcinoma (HCC). However, 1 issue remains open: what is the factor able to predict which patients will be long survivors?In the present study, we harnessed the potential of conditional survival, aiming at estimating the probability that a patient receiving sorafenib survives for more than 3 years.The present multicentric study was conducted on a cohort of 438 HCC patients. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities at 3 years.The 3-year conditional survival of patients without disease progression highlights that NLR and ECOG are the factors that most accurately predict the probability of long survival. The 3-year conditional survival of patients with disease progression showed a medium effect size for HCV status, alpha-fetoprotein and NLR at all time-points. Macro-vascular portal vein invasion, extra hepatic disease, and BCLC we have a large effect size at 6 months and a medium effect size at 12 and 24 months.Our findings support the use of baseline NLR for the identification of patients with a higher probability of long-survival. NLR should be used as a stratification factor in the forthcoming clinical trials on the drugs for the advanced HCC now in pipeline.
99
22
1
6
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib / Casadei-Gardini, A.; Dadduzio, V.; Rovesti, G.; Cabibbo, G.; Vukotic, R.; Rizzato, M. D.; Orsi, G.; Rossi, M.; Guarneri, V.; Lonardi, S.; D'agostino, D.; Celsa, C.; Andreone, P.; Zagonel, V.; Scartozzi, M.; Cascinu, S.; Cucchetti, A.. - In: MEDICINE. - ISSN 1536-5964. - 99:22(2020), pp. 1-6. [10.1097/MD.0000000000019958]
Casadei-Gardini, A.; Dadduzio, V.; Rovesti, G.; Cabibbo, G.; Vukotic, R.; Rizzato, M. D.; Orsi, G.; Rossi, M.; Guarneri, V.; Lonardi, S.; D'agostino, D.; Celsa, C.; Andreone, P.; Zagonel, V.; Scartozzi, M.; Cascinu, S.; Cucchetti, A.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1249290
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 8
social impact